Gregory Brown
Psychiatry · Shreveport, LANPI 1821058181
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $422,270 of the $494,713 with a category attached, or 85.4%. 21 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 31.1% of the total. 2025 is the largest year on record at $117,397, 2.2 times the $54,365 reported in 2019. Among psychiatry clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 987 payments — averaging $501.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$154K
- Neurocrine Biosciences, Inc.$138K
- Supernus Pharmaceuticals, Inc.$79K
- AbbVie$74K
- Ironshore Pharmaceuticals Inc.$29K
- Idorsia Pharmaceuticals US Inc$11K
- plus $9K from 15 others
What the payments were for
- Consulting fees$27,4036%
- Speaking & faculty fees$422,27085%
- Travel & lodging$23,1775%
- Food & beverage$21,8414%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 199 | $153,723 |
| Neurocrine Biosciences, Inc. | 167 | $138,026 |
| Supernus Pharmaceuticals, Inc. | 139 | $78,795 |
| AbbVie(2 entities) | 189 | $74,286 |
| Ironshore Pharmaceuticals Inc. | 60 | $29,379 |
| Idorsia Pharmaceuticals US Inc | 6 | $11,087 |
| Corium, LLC | 16 | $4,029 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 46 | $1,275 |
| Alkermes, Inc. | 50 | $1,050 |
| Lundbeck LLC | 39 | $680 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $631 |
| Sunovion Pharmaceuticals Inc. | 32 | $522 |
| Axsome Therapeutics, Inc. | 6 | $448 |
| E.r. Squibb & Sons, L.L.C. | 6 | $206 |
| Shire North American Group Inc | 10 | $181 |
| Johnson & Johnson | 4 | $177 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $109 |
| Teva Pharmaceuticals USA, Inc. | 2 | $48 |
| Vertical Pharmaceuticals, LLC | 2 | $29 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| Neos Therapeutics, LP | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$150,590
- INGREZZA$135,701
- QELBREE$72,909
- VRAYLAR$71,467
- Jornay PM 20mg capsules (Bottle of 100)$28,383
- QUVIVIQ$11,069
- Azstarys$3,717
- ABILIFY MAINTENA$629
- ARISTADA$500
- Auvelity$375
- TRINTELLIX$361
- CAPLYTA$250
- COBENFY$126
- INVEGA SUSTENNA$125
- INVEGA TRINZA$125
- ARISTADA INITIO$125
How this compares
$494,713 in reported general payments places this provider in the 95th percentile of 474 psychiatry providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 26 | $36,962 |
| RexultiBrexpiprazole | 15 | $24,923 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $3,032 |
| Duloxetine Hcl | 100 | $1,206 |
| Hydroxyzine Hcl | 115 | $940 |
| Amitriptyline Hcl | 31 | $787 |
| Aripiprazole | 37 | $781 |
| Hydroxyzine Pamoate | 24 | $549 |
| Doxepin Hcl | 19 | $475 |
| Ziprasidone Hcl | 14 | $468 |
| Oxcarbazepine | 17 | $451 |
| Bupropion XlBupropion Hcl | 37 | $393 |
| Lurasidone Hcl | 15 | $356 |
| Guanfacine Hcl | 12 | $314 |
| Clonazepam | 68 | $310 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $74,286 | $36,96226 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $153,723 | $24,92315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 psychiatry providers in Louisiana.
Other psychiatry in Shreveport
- Jasjit SinghShreveport$420K
- Suresh SabbenahalliShreveport$10K
- Guy BrannonShreveport$6K
- Christopher BernadasShreveport$6K
- Daniel FeeneyShreveport$5K
- Patrick HayesLake Charles$837K
- Maria CruseThibodaux$522K
- Larry WarnerBaton Rouge$495K
- Arwen PodestaNew Orleans$466K
- Roger BrownMandeville$216K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.